BioSig to Host Business Update Conference Call on November 18, 2020
November 12 2020 - 2:11PM
BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the
"Company"), a medical technology company commercializing a
proprietary biomedical signal processing platform designed to
improve signal fidelity and uncover the full range of ECG and
intra-cardiac signals, today announced that it would host a call on
November 18, 2020, at 4:15 PM ET. Kenneth L. Londoner, Chairman,
and CEO of BioSig Technologies, Inc. will review highlights from
the Company's third quarter of 2020 and discuss corporate
initiatives, including ongoing PURE EP™ System installations and
commercialization outlook.
Conference Call Details Date: Wednesday,
November 18, 2020 Time: 4:15 PM Eastern Time (ET) Dial in Number:
+1 877-407-8293 / 201-689-8349 A replay will be available for two
weeks starting on November 18, 2020, at approximately 7:15 PM ET.
To access the replay, please dial +1 877-660-6853 / 201-612-7415.
The conference ID# is 13713315.
BioSig's PURE EP™ System is currently installed in six medical
centers across the country. More than 350 patient cases have been
completed with the PURE EP™ System to date. BioSig is presently
enrolling patients in the clinical trial titled "Novel Cardiac
Signal Processing System for Electrophysiology Procedures (PURE EP
2.0 Study)" at Texas Cardiac Arrhythmia Research Foundation (TCARF)
in Austin, Texas and Mayo Clinic Florida Campus in Jacksonville,
Florida.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company's first product, PURE EP (tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024